Haemonetics (HAE) Scheduled to Post Quarterly Earnings on Monday
Haemonetics (NYSE:HAE) is scheduled to be announcing its Q414 earnings results on Monday, April 28th. Analysts expect the company to announce earnings of $0.58 per share and revenue of $244.87 million for the quarter. Haemonetics has set its FY14 guidance at $2.30-2.40 EPS.Parties that wish to register for the company’s conference call can do so using this link.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Monday, January 27th. The company reported $0.61 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.61. The company had revenue of $242.10 million for the quarter, compared to the consensus estimate of $243.71 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was down 2.1% on a year-over-year basis. On average, analysts expect Haemonetics to post $2.32 EPS for the current fiscal year and $2.25 EPS for the next fiscal year.
Shares of Haemonetics (NYSE:HAE) opened at 33.54 on Friday. Haemonetics has a one year low of $31.62 and a one year high of $45.90. The stock has a 50-day moving average of $34.25 and a 200-day moving average of $38.88. The company has a market cap of $1.740 billion and a P/E ratio of 46.67.
HAE has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Haemonetics in a research note on Friday, March 28th. They now have a $34.00 price target on the stock. On the ratings front, analysts at Benchmark Co. cut their price target on shares of Haemonetics from $46.00 to $41.00 in a research note on Tuesday, March 25th. Finally, analysts at Jefferies Group cut their price target on shares of Haemonetics from $45.00 to $38.00 in a research note on Tuesday, March 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $38.20.
Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.